We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allogene Therapeutics (ALLO) Up 3% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Allogene Therapeutics (ALLO - Free Report) . Shares have added about 3% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Allogene’s Q4 Earnings Top Estimates
Allogene incurred loss of 53 cents per share in fourth-quarter 2020, narrower than the Zacks Consensus Estimate of 56 cents as well as the year-ago quarter’s loss of 58 cents.
With no marketed products, the company did not record any revenues during the quarter.
Quarter in Detail
Research & development (R&D) expenses were $52.2 million, up 5.8% from the year-ago quarter.
General and administrative (G&A) expenses increased 12.6% year over year to $17.1 million.
The company had $1 billion in cash, cash equivalents and investments as of Dec 31, 2020, same as at the end of Sep 30, 2020.
Full-Year Results
Allogene did not report any revenues for the full year. The company incurred loss of $2.08 per share for 2020, wider than loss of $1.83 in the year-ago period.
2021 Guidance
Allogene issued its guidance for operating expenses in 2021, which is expected to be between $300 million and $330 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review. The consensus estimate has shifted 13.1% due to these changes.
VGM Scores
Currently, Allogene Therapeutics has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Allogene Therapeutics (ALLO) Up 3% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Allogene Therapeutics (ALLO - Free Report) . Shares have added about 3% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Allogene’s Q4 Earnings Top Estimates
Allogene incurred loss of 53 cents per share in fourth-quarter 2020, narrower than the Zacks Consensus Estimate of 56 cents as well as the year-ago quarter’s loss of 58 cents.
With no marketed products, the company did not record any revenues during the quarter.
Quarter in Detail
Research & development (R&D) expenses were $52.2 million, up 5.8% from the year-ago quarter.
General and administrative (G&A) expenses increased 12.6% year over year to $17.1 million.
The company had $1 billion in cash, cash equivalents and investments as of Dec 31, 2020, same as at the end of Sep 30, 2020.
Full-Year Results
Allogene did not report any revenues for the full year. The company incurred loss of $2.08 per share for 2020, wider than loss of $1.83 in the year-ago period.
2021 Guidance
Allogene issued its guidance for operating expenses in 2021, which is expected to be between $300 million and $330 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review. The consensus estimate has shifted 13.1% due to these changes.
VGM Scores
Currently, Allogene Therapeutics has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.